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Background: Local recurrence (LR) in osteosarcoma is associated with very poor prognosis. We sought to evaluate
which factors correlate with LR in patients who achieved complete surgical remission with adequate margins.
Patients and methods: We analyzed 1355 patients with previously untreated high-grade central osteosarcoma of
the extremities, the shoulder and the pelvis registered in neoadjuvant Cooperative Osteosarcoma Study Group trials
between 1986 and 2005. Seventy-six patients developed LR.
Results: Median follow-up was 5.56 years. No participation in a study, pelvic tumor site, limb-sparing surgery, soft
tissue infiltration beyond the periosteum, poor response to neoadjuvant chemotherapy, failure to complete the planned
chemotherapy protocol and biopsy at a center other than the one performing the tumor resection were significantly
associated with a higher LR rate. No differences were found for varying surgical margin widths. Surgical treatment at
centers with small patient volume and additional surgery in the primary tumor area, other than biopsy and tumor
resection, were significantly associated with a higher rate of ablative surgery.
Conclusions: Patient enrollment in clinical trials and performing the biopsy at experienced institutions capable of
undertaking the tumor resection without compromising the oncological and functional outcome should be pursued in
the future.
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introduction
Complete surgical resection of the primary tumor is one of the
prerequisites for long-term survival in osteosarcoma [1, 2], and
the development of local recurrence (LR) is associated with very
poor prognosis [3, 4]. Several studies have shown that pelvic
tumor site [5, 6], response to preoperative chemotherapy [7, 8]
and the quality of surgical margins [7, 9] according to
Enneking’s classification [10] correlate with LR, the latter being
to date the only known prognostic factor which can be
influenced by the treating physicians.
All available studies have concentrated on the comparison of
inadequate (intralesional, marginal or contaminated [11]) and
adequate (wide or radical) margins [2, 4–7, 9, 12–14].
However, no study has examined which surgical margin width
in bone and soft tissue is necessary to ensure local control
in patients with adequate margins, with arbitrary
recommendations in well-known textbooks for orthopedic
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surgery varying from 3 to 7 cm [15, 16]. Furthermore, previous
studies included patients after intralesional resections [2, 5–7,
9, 12–14], in whom the LR can be viewed as a secondary
progression of residual tumor. Multivariate analyses have,
expectedly, shown that inadequate margins is the most
important factor influencing LR [9, 17], possibly obscuring the
importance of other factors in patients undergoing wide or
radical resections, as is the case for the vast majority of
osteosarcoma patients today [9, 14, 18]. Moreover, several
tumor- and treatment-related factors have never been
examined.
As a result, we conducted this study of osteosarcoma patients
with adequate surgical margins to evaluate which factors
correlate with LR and identify potential improvements in the
multimodal treatment algorithm.
patients and methods
patients
Between January 1986 and December 2005, 1802 consecutive patients with
previously untreated histologically confirmed high-grade central
osteosarcoma of the extremities, the shoulder and the pelvic girdle were
enrolled in neoadjuvant trials of the Cooperative Osteosarcoma Study
Group (COSS) and achieved a complete surgical remission of all detectable
tumor foci with adequate margins. Patients with primary metastases were
included if they achieved complete surgical remission, as 5-year overall
survival (OS) rates of 50% have been shown for this subgroup [19]. All
studies were approved by the appropriate ethics and/or protocol review
committees. Informed consent was required from all patients and/or their
legal guardians, depending on the patients’ age.
Fourteen patients underwent secondary amputations shortly after limb-
sparing procedures due to surgical complications and were not included in
this analysis. Neither progress letters nor surgery and pathology reports
were available for 433 patients, leaving 1355 patients as subjects of this
study. A LR developed in 76 of those patients.
As all COSS trials mainly targeted patients younger than 40 years of age
with primary, localized, high-grade central osteosarcoma of the extremities,
868 patients were actual study participants. The remaining 487 patients
were registered in the COSS registry, treated according to the same general
guidelines and followed prospectively.
diagnostic staging, primary treatment and follow-up
Conventional radiographs of the affected bone were required in all studies,
whereas the use of cross-sectional imaging modalities [computed
tomography (CT) and magnetic resonance imaging (MRI) scans] depended
on their availability. Chest radiographs and 99Tc-methylene diphosphonate
bone scans were used to detect metastases, while chest CT scans became
mandatory in 1991. The great majority of the biopsy specimens were
reviewed by the protocols’ reference pathologists’ panels.
The details of primary treatment have been described elsewhere [1, 20,
21]. Briefly, all patients were to receive pre- and postoperative
chemotherapy according to the COSS protocol active at the time of
enrollment. All protocols included high-dose methotrexate with leucovorin
rescue, doxorubicin and cisplatin. Ifosfamide was used in varying
combinations, while carboplatin and etoposide were introduced in the
COSS-96 trial for high-risk patients with poor response to chemotherapy.
Primary tumor surgery was scheduled between weeks 9 and 11 in all
protocols. In the presence of primary metastases, the sequence of surgical
procedures varied, but resection of the primary tumor was usually carried
out before resection of metastases [19].
Routine follow-up included clinical examinations and conventional
radiographs of the primary tumor site and the chest at regular intervals. A
full diagnostic work-up was required in all cases of suspected local or
systemic relapse. The diagnosis of recurrence was based on the assessment
of the treating institutions.
data collection and definition of variables
Data concerning patient demographics, tumor characteristics, first-line
therapy and follow-up were collected prospectively, coded and entered into
an electronic database as previously described [1]. Further details regarding
tumor characteristics at presentation and primary treatment were collected
retrospectively from pathology, surgery and radiology reports, progress
letters, status reports forms and telephone notes available at the data center.
The study charts of all 1802 patients were reviewed and relevant
information was coded into following variables: age, with a cut-off at the
cohort’s median; soft tissue infiltration—histologically documented tumor
infiltration of the soft tissue beyond the periosteum; surgical margin width
in bone/soft tissue—the distance of the tumor to the surgical margin in
bone/soft tissue recorded in the pathology report; pathological
fracture—the presence of a pathological fracture at diagnosis or its
development during treatment or at an unknown point; treatment of
pathological fracture—conservative or operative; treatment
modification—whether the planned chemotherapy protocol could be
administered to its end or not; additional surgery—surgical procedures in
the primary tumor area, other than biopsy and resection; center performing
the biopsy; center performing the primary tumor resection; center
volume—big/small = centers operating more/less than one patient per year
per 5-year period.
statistical analysis
This analysis is based on follow-up data as of May 2008. All parameters
were first evaluated with univariate techniques. Fisher’s exact test was used
to compare unrelated samples. Nonparametric analyses were carried out
with the Mann–Whitney U test. OS at 5 and 10 years, LR rates and
postrelapse survival at 2 and 5 years were calculated with the Kaplan–Meier
method [22]. Survival curves were compared with the log-rank test [23].
Multivariate analysis was carried out with the Cox proportional hazards
model [24]. Only variables that were significantly associated with the
development of LR in univariate analysis were included in the multivariate
model. Statistical calculations were carried out with the SPSS software
version 16.0 (SPSS, Inc., Chicago, IL). All P values are two-sided; a P < 0.05
was considered significant.
results
patient and tumor characteristics
There were 805 male (59.4%) and 550 female (40.6%) patients.
The median age at diagnosis was 15 years (range, 2–70 years;
mean, 16.29 years). Most patients had at diagnosis a primary
(97.9%), nonmetastatic (89.0%) osteosarcoma of the lower
extremity (85.4%) and were study participants (64.1%;
Table 1). The distribution of patients in 5-year period groups
is shown in Table 2.
Tumor size ranged from 1.5 to 31 cm (median, 9 cm; mean,
9.56 cm). According to the American Joint Committee on
Cancer staging system (6th edition) [25], 731 patients (53.9%)
had T2 tumors (Table 1). Tumor infiltration of the soft tissue
beyond the periosteum had been documented in 321 patients
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Table 1. Univariate analysis of local recurrence and limb-salvage rates
Patients % Local recurrence rate (%) P (log rank) Limb-sparing surgery (%) P (Fisher’s
exact)2-year SE 5-year SE Yes No
Eligible 1355 100 3.8 0.5 5.9 0.7
Age
<16 766 56.5 3.3 0.7 4.9 0.8
0.135
59.3 40.7
<0.0001
‡16 589 43.5 4.4 0.9 7.3 1.1 73.2 26.8
Sex
Male 805 59.4 3.6 0.7 5.8 0.9
0.807
64.3 35.7
0.597
Female 550 40.6 3.9 0.8 6.1 1.1 66.7 33.3
Secondary osteosarcoma
No 1327 97.9 3.7 0.5 5.9 0.7
0.724
65.0 35.0
0.07
Yes 28 2.1 7.3 5.0 7.3 5.0 82.1 17.9
Primary metastases
No 1206 89.0 3.5 0.5 5.5 0.7
0.068
66.6 33.4
0.006
Yes 149 11.0 6.3 2.0 9.3 2.6 55.0 45.0
Study participant
Yes 868 64.1 1.9 0.5 3.6 0.7
<0.0001
64.0 36.0
0.153
No 487 35.9 7.0 1.2 10.0 1.5 68.0 32.0
Tumor site
Pelvis 35 2.6 18.0 6.7 31.7 9.1
<0.0001
77.1 22.9
0.153
Extremity all 1320 97.4 3.4 0.5 5.3 0.7 65.0 35.0
Lower extremity 1157 87.7 3.2 0.5 5.2 0.7
0.711
62.1 37.9
<0.0001
Upper extremity 163 12.3 4.5 1.6 5.9 1.9 85.9 14.1
T stage
T1 575 42.4 3.2 0.7 4.7 0.9
0.227
75.1 24.9
<0.0001
T2 731 53.9 4.1 0.8 6.9 1.0 57.2 42.8
0.244 0.846
T3 28 2.1 11.0 6.0 11.0 6.0 60.7 39.3
Unknown 21 1.6
T1 versus T3 0.112 0.117
Soft tissue infiltration
No 531 39.2 3.4 0.7 4.1 0.9
0.002
79.3 20.7
<0.0001
Yes 321 23.7 6.8 1.4 9.4 1.7 53.3 46.7
Unknown 503 37.1
Pathological fracture
No 1176 86.8 3.3 0.5 5.6 0.7
0.208
66.7 33.3
0.017
Yes 175 12.9 7.2 2.0 8.0 2.1 57.1 42.9
At diagnosis 111 63.4 5.6 2.2 5.6 2.2
0.163
66.7 33.3
0.0004
During treatment 41 23.4 10.3 4.9 13.5 5.7 34.1 65.9
At unknown point 23 13.2
Unknown 4 0.3
No versus during
treatment
0.047 <0.0001
Treatment of pathological
fracture (n = 175)
Conservative 158 90.3 7.2 2.1 8.1 2.3
0.875
57.6 42.3
0.799
Operative 17 9.7 7.1 6.9 7.1 6.9 52.9 47.1
Limb-sparing surgery
Yes 885 65.3 4.7 0.7 7.5 0.9
0.001
No 470 34.7 2.0 0.7 2.8 0.8
Type of surgery
Ablative 230 17.0 2.7 1.1 3.2 1.2
0.048
Limb sparing 885 65.3 4.7 0.7 7.5 0.9
0.003
Rotationplasty 240 17.7 1.3 0.7 2.4 1.0
Type of resectiona
Wide 1126 83.1 3.6 0.6 6.2 0.8
0.613
Radical 229 16.9 4.5 1.4 4.5 1.4
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(23.7%), 531 patients had no infiltration (39.2%), while no
adequate data were available for 503 patients (37.1%).
Among 175 patients (12.9%) with a pathological fracture,
158 patients (90.3%) underwent conservative and 17 (9.7%)
operative treatment. Seventy patients (5.2%) had additional
surgery in the primary tumor area (Table 1).
primary treatment
All eligible patients underwent pre- and postoperative
chemotherapy. A good histological response (<10% of the
tumor viable in histology) was found in 826 patients (61.0%;
Table 1). Treatment modifications were recorded in 211
patients (15.6%).
Limb-sparing procedures were carried out in 885 patients
(65.3%), rotationplasty in 240 (17.7%) and amputations in 230
patients (17.0%). The surgical margin width in bone was only
considered in the 1126 patients (83.1%) who underwent a wide
and not a radical surgical resection [10]. Available for 909
patients (80.7%), it ranged from 1 to 350 mm (median, 50.0
mm; mean, 62.3 mm). For limb-sparing procedures, the
median and mean amounted to 45.0 and 48.1 mm, respectively.
Forty-seven patients had a margin width in bone of up to
10 mm and 76 patients between 11 and 20 mm.
The surgical margin width in soft tissue was considered only in
the 224 patients with a wide surgical resection and a documented
infiltration of the soft tissue beyond the periosteum. Available
for 115 patients (51.3%), it had a median value of 5 mm (range,
1–120 mm; mean, 12.9 mm). Due to the high amount of
missing data, this factor was not evaluated further.
The tumor resection was carried out at 107 different centers,
with 1034 patients (76.3%) operated in big and 321 patients
(23.7%) in small centers. Tumor resections per center ranged
from 1 to 346 (median, 3; mean, 12.7). The biopsy was carried
out at a different center than the resection in 406 patients
(30.0%; Table 1).
outcome
After a median follow-up of 5.56 years (range, 0.64–20.8 years)
for all patients and 6.67 years (same range) for survivors, the
rate of LR for this selected group of patients at 2 and 5 years
was 3.8 and 5.9% respectively. OS at 5 and 10 years was 34.9
Table 2. Patient distribution per 5-year periods
N %
1986–1990 233 17.2
1991–1995 324 23.9
1996–2000 445 32.8
2001–2005 353 26.1
Table 1. (Continued)
Patients % Local recurrence rate (%) P (log rank) Limb-sparing surgery (%) P (Fisher’s
exact)2-year SE 5-year SE Yes No
Surgical margin width bone
(£2 cm only, n = 123), mm
1–10 47 38.2 4.5 3.1 9.9 4.7
0.776
11–20 76 61.8 6.9 3.0 11.5 3.8
Response
Good 826 61.0 1.8 0.5 3.1 0.6
<0.0001
67.4 32.6
0.045
Poor 515 38.0 6.7 1.1 10.2 1.5 61.9 38.1
Unknown 14 1.0
Additional surgical
procedures
No 1095 80.2 4.3 0.6 6.6 0.8
0.402
66.7 33.4
0.006
Yes 70 5.2 4.5 2.5 11.0 4.4 50.0 50.0
Unknown 190 14.0
Modification of treatment
plan
No 1044 77.0 2.7 0.5 4.4 0.7
0.0001
64.1 35.9
0.343
Yes 211 15.6 7.9 1.9 11.2 2.3 67.8 32.2
Unknown 100 7.4
Center performing the
biopsy/the tumor resection
Same 882 65.1 2.6 0.5 4.2 0.7
0.0001
65.6 34.4
0.572
Different 406 30.0 6.4 1.2 10.1 1.6 64.0 36.0
Unknown 67 3.9
Center volume
Big 1034 76.3 3.8 0.6 6.1 0.8
0.761
69.9 30.1
<0.0001
Small 321 23.7 3.6 1.1 5.4 1.3 50.5 49.5
aAccording to the Enneking classification [10].
SE, standard error.
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and 21.2% in the LR group, compared with 80.1 and 74.4% in
the nonlocal recurrence (NLR) group (P < 0.0001; Figure 1).
Survival after local relapse at 5 and 10 years amounted to 21.7
and 19.0%, respectively.
The median time to LR was 1.57 years (range, 0.54–8.56
years; mean, 1.99 years). Patients who developed a LR within
the first 12 months had a significantly lower OS than those
relapsing between 13 and 24 months (P < 0.0001), who in turn
faired worse than those with a local relapse developing after 24
months (P < 0.0001; Figure 2).
Sixty-three patients in the LR group (82.9%) and 393
patients in the NLR group (30.8%) developed secondary
metastases (P < 0.0001). Twenty-one patients in the LR group
(27.6%) developed metastases after LR, 32 (42.1%)
synchronously and 10 (13.2%) before LR. OS was significantly
better in patients with secondary metastasis following LR
compared with patients developing metastases simultaneously
(P = 0.002) or before LR (P = 0.021). Long-term disease-free
survival was not observed in patients in whom secondary
metastasis preceded LR.
univariate analysis
There was no significant correlation between patient age (with
a cutoff at 16 years), sex, secondary osteosarcoma or primary
metastasis and LR rate (Table 1). On the other hand, patients
participating in a study faired significantly better than
those who were only registered and followed prospectively
(P < 0.0001; Table 1).
Regarding the primary tumor characteristics, pelvic
localization was associated with a significantly higher LR rate,
as was soft tissue infiltration (Table 1). OS was significantly
higher in patients without soft tissue infiltration (85.1 and
79.7% versus 62.7 and 55.9% at 5 and 10 years, P < 0.0001).
No significant difference was found between tumors of the
lower and upper extremities (P = 0.711). Neither tumor size
(P = 0.234) nor T stage (Table 1) correlated with LR. Patients
with pathological fractures developing during treatment had
a higher LR rate compared with patients with no pathological
fractures (Table 1).
Limb-sparing procedures were associated with a higher LR
rate (Table 1), with no differences in disease-specific survival
(P = 0.118). Surgical margin width in bone did not correlate
with the LR rate, neither in the whole group (P = 0.126) nor in
subgroup analyses of limb-sparing procedures only (P = 0.692),
margin width of £10 mm only (P = 0.223), £ 20 mm only
(P = 0.379), or when comparing a width of £10 mm with
a width of 11 to 20 mm (Table 1).
Patients with a good histological response as well as those
who were able to complete the planned chemotherapy protocol
had fewer LRs (Table 1). Additional surgical procedures and
surgical treatment in a small center did not lead to a higher LR
rate, but both factors were significantly associated with
a higher rate of ablative surgery (Table 1). Finally, a biopsy at
a center other than the one performing the tumor resection
was also associated with a significantly higher LR rate
(P = 0.0001).
multivariate analysis
Soft tissue infiltration was not included in multivariate analysis
due to the high amount of missing data. All other factors with
a significant correlation to LR in univariate analysis retained
their significance in the multivariate model (Table 3).
Table 3. Multivariate analysis of local recurrence-free survival with the
Cox proportional hazards model
Local recurrence-free survival
RR 95% CI P
Not a study participant 1.86 1.07–3.21 0.027
Pelvic site 3.18 1.51–6.73 0.002
Limb-sparing surgery 2.99 1.52–5.92 0.002
Poor response 3.76 2.91–6.44 <0.0001
Modification of treatment
plan
2.03 1.18–3.49 0.011
Tumor resection carried out
at a different center than
the biopsy
2.23 1.35–3.68 0.002
RR, relative risk; CI, confidence intervals.Figure 2. Overall survival according to time to local recurrence.
Figure 1. Overall survival according to the presence of local recurrence.
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discussion
Our analysis included a selected group of 1355 osteosarcoma
patients who achieved a first complete surgical remission with
adequate margins, treated over a period of 20 years at 107
different surgical institutions. Inevitably, differences in the
surgical philosophy over the years and between the centers
caused for some inhomogeneity in our patient cohort, which is
one of the limitations of this study, while another is its
retrospective nature. However, we believe that the strict
inclusion criterion of a histologically documented wide or
radical surgical margin and the high number of patients
analyzed compensate for any such inconsistencies.
Another limitation lies in the fact that approximately
a quarter of the patients were surgically treated at institutions
with limited experience, operating less than one patient per
year. On the other hand, we included this factor in our analysis
to evaluate the hypothesis that experienced centers offer better
treatment to patients with a rare tumor such as osteosarcoma.
While no differences in LR rates were found, small centers
carried out amputations with a significantly higher frequency
than big ones. Limb-sparing surgery has been shown to
correlate with an improved functional outcome [26, 27], which
is why it is the treatment of choice in most cases, provided that
the oncological outcome is not put at risk. Therefore, our
results support the need to concentrate osteosarcoma care in
fewer centers with more experience.
Whether limb-sparing surgery correlates to LR remains
controversial, with some studies finding no influence [28, 29]
and others reporting a higher LR rate for limb-sparing
procedures [14, 18], as was the case in our analysis. It should be
noted that the former studies were monoinstitutional and the
latter multicentric, which implies a correlation between
surgeon volume and local control after limb-sparing
procedures. Our data could not confirm this hypothesis, but
the calculations were also not adjusted for case-mix.
The width of surgical margins in bone did not influence the
LR rate in patients undergoing wide resections, even in patients
with a comparatively narrow margin. To our knowledge, this is
the first time this factor has been evaluated in detail. Our results
contradict the need to resect a minimum of 3 cm of healthy
bone to ensure local control [15, 16], especially considering that
the intraosseous tumor extent in MRI scans has been shown to
correlate excellently with the actual tumor extent in pathology
[30, 31].
Provided that an adequate surgical margin is ensured, the
preservation of a greater amount of healthy bone in more
conservative approaches increases the amount of patients who
qualify for joint-preservation procedures with an improved
functional outcome [32, 33]. Furthermore, it improves the
biomechanical result in patients undergoing endoprosthetic
replacement by improving the length ratio of the remaining
bone to the prosthesis [34]. Aseptic loosening, the most
common complication following endoprosthetic replacement
[35, 36], has been found to correlate to the amount of bone
resected [35]. Moreover, its surgical treatment almost always
requires a further resection of the remaining bone [36], a factor
that also underlines the need to avoid the unnecessary sacrifice
of healthy bone during the initial tumor resection procedures.
Participation in a study protocol was associated with a lower
LR rate. Picci et al. [37] recently reported a higher LR rate for
patients who were not candidates for study protocols, possibly
due to the more unfavorable characteristics of these patients.
However, many of the patients in the COSS register were not
enrolled in study protocols despite being eligible because
systemic treatment did not commence within 3 weeks of
diagnostic biopsy, an exclusion criterion in previous COSS
studies. Moreover, lack of participation in a study remained an
independent prognostic factor for LR in multivariate analysis.
While reasons for this remain unclear, recruitment in clinical
trials has been shown to lead to improved OS as well [38, 39],
possibly due to a better adherence to treatment guidelines.
The influence of systemic treatment on LR has been well
documented, with poor responders being at higher risk [7, 8].
Another aspect of this influence appears to be the failure to
complete the planned adjuvant chemotherapy that was
associated with a higher LR rate in this study. Given the
retrospective nature of this analysis and that the reasons for
treatment modifications were not always retraceable, the
clinical significance of this finding will probably be limited,
although it could serve as an additional argument to patients
unwilling to subject themselves to several months of systemic
treatment.
A poorly performed biopsy has been related to an increased
complication rate, delays in treatment and may compromise
limb salvage [40–42]. However this is, to our knowledge, the first
time it has been shown that patients are at an increased risk of LR
if their biopsy is carried out at a center other than the one doing
the definitive tumor resection, regardless of the quality of the
biopsy. The importance of this finding lies in the fact that this
factor can be eliminated by a different surgical approach from the
treating physicians, leading to a significantly lower LR rate.
The presence of soft tissue infiltration beyond the periosteum
should not be confused with cortex breach and extraosseous
tumor spread as the periosteum poses an important barrier to
the tumor and is elevated from the cortex but not breached
even in cases with a large extraosseous tumor extent [43].
Spanier et al. [44] have shown that the breach of the
periosteum correlates with a decreased OS and LR-free survival,
both of which findings we were able to confirm in our analysis.
However, many studies have ignored the significance of this
factor and more than a third of the pathology reports in our
analysis made no mention to it. We therefore believe that this
aspect of tumor extent should be included in prospective
evaluations in future studies as it has the potential to contribute
significantly to an accurate tumor staging and the development
of risk-adapted treatment plans.
In conclusion, our analysis of a large series of osteosarcoma
patients who achieved a first complete surgical remission with
adequate margins identified several independent prognostic
factors for local control and underscored the significance of
others. Some of these factors cannot be influenced as they are
tumor related, but may improve patient stratification in future
trials. Others, such as patient enrollment in clinical trials and
performing the biopsy at experienced institutions capable of
undertaking tumor resection without compromising the
oncological and functional outcome, should be pursued in the
future.
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